がん化学療法誘発性悪心および嘔吐治療薬市場：タイプ別、薬剤クラス別、投与経路別、流通チャネル別、地域別

がん化学療法誘発性悪心および嘔吐治療薬市場は、2025年には34億3,100万米ドルと推定され、2032年には50億5,760万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は5.7%で成長すると予測されています。

がん患者の治療は、悪心および嘔吐（N&V）の予防とコントロールを優先しなければならないです。化学療法による吐き気・嘔吐（N&V）の最も一般的で動揺させる急性有害作用の1つは、がん治療です。これは患者のQOLを著しく低下させ、最大80％の患者に起こる。吐き気の知覚的な感覚は、上腹部および/または喉の奥の不快な波のような感覚であり、嘔吐につながることがあります。嘔吐とは、胃、十二指腸、空腸の内容物が口腔管を通って激しく排出されることで、嘔吐と呼ばれます。乾性嘔吐としても知られるレッチングは、嘔吐物の排出を伴わない嘔吐の胃および食道運動を伴う。悪心および嘔吐（N&V）を制御する神経生理学的システムの理解は進んでいます。中枢神経系は両者を調節または媒介するが、その方法はさまざまです。自律神経系は吐き気を引き起こすメカニズムです。

嘔吐時には求心性入力の収束を含む複雑な反応が刺激されます。化学受容器トリガーゾーン、嘔吐中枢（孤束核にあるといわれる）、消化管の腸クロム親和細胞の神経伝達物質が求心性インパルスを発します。これらの神経伝達物質には、セロトニン、サブスタンスP、ドーパミンなどがあります。これらの信号は呼吸中枢、唾液分泌中枢、腹筋に送られます。N&V症状をもたらすこれらいくつかの経路の相対的重要性は複雑です。薬剤の多様な催吐性（内因性催吐性および緩和変数［すなわち、投与量、投与方法および曝露期間］）および催吐性プロファイル（すなわち、症状発現までの時間、強さおよび持続時間）を説明することが提案されています。

市場力学

化学療法誘発性悪心および嘔吐（CINV）薬は、悪心および嘔吐を予防するために化学療法を受ける患者に投与されます。化学療法を受ける患者の増加は、予測期間中の市場成長を促進すると予想されます。例えば、米国疾病予防管理センターが提供したデータによると、2022年11月、米国では毎年100万人以上のがん患者が外来の腫瘍科クリニックで化学療法や放射線療法を受けています。

本調査の主な特徴

• 本レポートでは、世界のがん化学療法誘発性悪心および嘔吐治療薬市場を詳細に分析し、2024年を基準年とした予測期間2025-2032年の市場規模およびCAGRを掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 世界のがん化学療法誘発性悪心および嘔吐治療薬市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界のがん化学療法誘発性悪心および嘔吐治療薬市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界のがん化学療法誘発性悪心および嘔吐治療薬市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 主な発展
• PEST分析
• PORTERの分析
• 規制シナリオ
• 合併、提携、買収のシナリオ
• 製品の発売/承認
• 疫学

第4章 世界のがん化学療法誘発性悪心および嘔吐治療薬市場-COVID-19の影響分析

• 経済への影響
• ヘルスケア分野への全体的な影響
• COVID-19疫学

第5章 世界のがん化学療法誘発性悪心および嘔吐治療薬市場、タイプ別、2020年～2032年

• 急性CINV
• 遅延CINV
• 予期性の悪心および嘔吐
• 画期的CINV/難治性CINV

第6章 世界のがん化学療法誘発性悪心および嘔吐治療薬市場、薬剤クラス別、2020年～2032年

• ドーパミン受容体拮抗薬
• メトクロプラミド
• クロルプロマジン
• プロクロルペラジン
• ハロペリドール
• ドロペリドール
• その他
• セロトニン（5-HT3）受容体拮抗薬
• オンダンセトロン
• グラニセトロン
• パロノセトロン
• ドラセトロン
• その他
• サブスタンスP/NK-1拮抗薬
• アプレピタント
• フォサプレピタント
• ネットピタント
• その他
• コルチコステロイド
• デキサメタゾン
• メチルプレドニゾロン
• その他

第7章 世界のがん化学療法誘発性悪心および嘔吐治療薬市場、投与経路別、2020年～2032年

• 経口
• 非経口
• 経皮パッチ

第8章 世界のがん化学療法誘発性悪心および嘔吐治療薬市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 世界のがん化学療法誘発性悪心および嘔吐治療薬市場、地域別、2020年～2032年

• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• 中東
  • GCC
  • イスラエル
  • その他中東
• アフリカ
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第10章 競合情勢

• Eisai Co., Ltd.
• Pharmanovia
• Novartis AG
  • Company Highlight
• Merck & Co., Inc.
  • Company Highlight
• Helsinn Healthcare SA
• Reddy's Laboratories Ltd.
• Validus Pharmaceuticals LLC
• LGM Pharma
• Astellas Pharma Inc.
• AdvaCare Pharma
• Norgine
• PV Pharma
• Fresenius Kabi
• Lupin
• Hetero Healthcare Limited.
• Sino Biopharmaceutical Limited
• Glenmark Pharmaceuticals Ltd.
• Otsuka Pharmaceutical Co., Ltd
• OPKO Health, Inc.
• Weefsel Pharma
• Pfizer Inc.
• Rosemont Pharmaceuticals Ltd.
• Starton Therapeutics

第11章 セクション

• 調査手法
• 出版社について

Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market is estimated to be valued at USD 3,431.0 Mn in 2025 and is expected to reach USD 5,057.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.7% from 2025 to 2032.

Treatment for cancer patients must prioritize preventing and controlling nausea and vomiting (N&V). One of the most prevalent and upsetting acute adverse effects of chemotherapy-induced nausea and vomiting (N&V) is cancer treatment. It can significantly lower a patient's quality of life and happens in up to 80% of patients. The perceptual feeling of nausea is an unpleasant, wave-like sensation in the epigastrium and/or back of the throat that may lead to vomiting (emesis). Emesis, the violent evacuation of stomach, duodenal, or jejunal contents through the oral canal, is referred to as vomiting. Retching, also known as dry heaves, involves the stomach and esophageal motions of vomiting without the evacuation of vomitus. Understanding the neurophysiological systems that regulate nausea and vomiting (N&V) has advanced. The central nervous system regulates or mediates both, but through different ways. The autonomic nervous system is the mechanism that causes nausea.

A complicated response that includes the convergence of afferent input is stimulated during vomiting. Neurotransmitters in the chemoreceptor trigger zone, the vomiting center (said to be situated in the nucleus tractus solitarius), and enterochromaffin cells in the gastrointestinal tract emit efferent impulses. These neurotransmitters include serotonin, substance P, and dopamine. These signals are sent to the respiratory center, salivation center, and abdominal muscles. The relative importance of these several routes, which result in N&V symptoms, is complicated. It is proposed to explain agents' varying emetogenicity (intrinsic emetogenicity and mitigating variables [i.e., dose, administration method, and exposure length]) and emetogenic profile (i.e., time to onset, intensity, and duration of symptoms).

Market Dynamics

Chemotherapy-induced nausea and vomiting (CINV) drugs are given to patients who undergo chemotherapy treatment to prevent nausea and vomiting. An increase in the number of patients undergoing chemotherapy is expected to drive the market growth over the forecast period. For instance, according to the data provided by the Centers for Disease Control and Prevention, in November 2022, more than 1 million cancer patients receive chemotherapy or radiation in an outpatient oncology clinic in the U.S. each year.

Key features of the study:

• This report provides an in-depth analysis of the global cancer chemotherapy associated nausea and vomiting therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cancer chemotherapy associated nausea and vomiting therapeutics market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eisai Co., Ltd., Pharmanovia, Novartis AG, Merck & Co., Inc., Helsinn Healthcare SA, Dr. Reddy's Laboratories Ltd., Validus Pharmaceuticals LLC, LGM Pharma, Astellas Pharma Inc., AdvaCare Pharma, Norgine, PV Pharma, Fresenius Kabi, Lupin, Hetero Healthcare Limited., Sino Biopharmaceutical Limited, Glenmark Pharmaceuticals Ltd., Otsuka Pharmaceutical Co., Ltd, OPKO Health, Inc., Weefsel Pharma, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Starton Therapeutics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global cancer chemotherapy associated nausea and vomiting therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer chemotherapy associated nausea and vomiting therapeutics market

Detailed Segmentation:

• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type:
  • Acute CINV
  • Delayed CINV
  • Anticipatory nausea and emesis
  • Breakthrough CINV/Refractory CINV
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Drug Class:
  • Dopamine Receptor Antagonists
  • Metoclopramide
  • Chlorpromazine
  • Prochlorperazine
  • Haloperidol
  • Droperidol
  • Others
  • Serotonin (5-HT3) receptor Antagonists
  • Ondansetron
  • Granisetron
  • Palonosetron
  • Dolasetron
  • Others
  • Substance P/NK-1 Antagonists
  • Aprepitant
  • Fosaprepitant
  • Netupitant
  • Others
  • Corticosteroids
  • Dexamethasone
  • Methylprednisolone
  • Others
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration:
  • Oral
  • Parenteral
  • Transdermal Patch
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Eisai Co., Ltd.
  • Pharmanovia
  • Novartis AG
  • Merck & Co., Inc.
  • Helsinn Healthcare SA
  • Reddy's Laboratories Ltd.
  • Validus Pharmaceuticals LLC
  • LGM Pharma
  • Astellas Pharma Inc.
  • AdvaCare Pharma
  • Norgine
  • PV Pharma
  • Fresenius Kabi
  • Lupin
  • Hetero Healthcare Limited.
  • Sino Biopharmaceutical Limited
  • Glenmark Pharmaceuticals Ltd.
  • Otsuka Pharmaceutical Co., Ltd
  • OPKO Health, Inc.
  • Weefsel Pharma
  • Pfizer Inc.
  • Rosemont Pharmaceuticals Ltd.
  • Starton Therapeutics.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Key Developments
• PEST Analysis
• PORTER's Analysis
• Regulatory Scenario
• Merger, Collaboration and Acquisition Scenario
• Product Launches/Approvals
• Epidemiology

4. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market- COVID-19 Impact Analysis

• Economic Impact
• Overall Impact on Healthcare Sector
• COVID-19 Epidemiology

5. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Type, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Acute CINV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Delayed CINV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Anticipatory nausea and emesis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Breakthrough CINV/Refractory CINV
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

6. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Drug Class, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Dopamine Receptor Antagonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Metoclopramide
• Chlorpromazine
• Prochlorperazine
• Haloperidol
• Droperidol
• Others
• Serotonin (5-HT3) receptor Antagonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Ondansetron
• Granisetron
• Palonosetron
• Dolasetron
• Others
• Substance P/NK-1 Antagonists
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Aprepitant
• Fosaprepitant
• Netupitant
• Others
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Dexamethasone
• Methylprednisolone
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

7. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Route of Administration, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Transdermal Patch
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

8. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Distribution Channel, 2020 - 2032, (US$ Million)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Million)

9. Global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market, By Region, 2020 - 2032, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • UK
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Eisai Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pharmanovia
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novartis AG
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Merck & Co., Inc.
  • Company Highlight
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Helsinn Healthcare SA
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Reddy's Laboratories Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Validus Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• LGM Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• AdvaCare Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Norgine
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• PV Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Fresenius Kabi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Lupin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Hetero Healthcare Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sino Biopharmaceutical Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Glenmark Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Otsuka Pharmaceutical Co., Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• OPKO Health, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Weefsel Pharma
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Rosemont Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Starton Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Section

• Research Methodology
• About Us